TrumpRx latest news today: TrumpRx explained: How Trump’s new drug price deals with 9 pharma companies could save patients money
Trump’s Statement Today Targets High Drug Costs in the US
The deals include some of the biggest names in the pharmaceutical industry, including Bristol Myers Squibb, Gilead Sciences, Merck and Roche’s US unit Genentech. According to Reuters, Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK also agreed to participate.
Under the agreements, each company will lower the prices of most drugs it sells through Medicaid, the government health program for low-income Americans. Officials described the expected impact as “huge savings” on commonly used drugs, but did not disclose specific figures.
The move comes as U.S. consumers currently pay much more for prescription drugs than patients in other developed countries, often nearly three times more; This is something Trump has emphasized repeatedly.
ALSO READ: Bowen Yang leaves Saturday Night Live cast: What SNL fans can expect in the latest episode – Here’s everything you need to know
TrumpRx Program Could Lower Cash-Pay Drug Costs Nationwide
Beyond Medicaid, the deals also potentially include lower cashback prices for certain drugs sold directly to consumers through the TrumpRx.gov website. Drugmakers also agreed that new drugs launched in the United States should not be priced higher than those in other rich countries. In return, participating companies could receive a three-year exemption from tariffs and commit to expanding production.
Merck to Offer Discounts on Diabetes Drugs Under TrumpRx
Merck detailed its plans, saying it would sell diabetes treatments Januvia, Janumet and Janumet XR directly to U.S. consumers at about 70% off list prices, according to a Reuters report. These drugs are expected to face generic competition next year. If approved, Merck’s experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels. Enlicitide is expected to undergo expedited review by the FDA. ALSO READ: Biggest tax refund season of all time? How Trump’s ‘Big Beautiful Bill’ could boost 2026 paychecks and who would benefit most?
Big Pharma Makers Sign on to Trump Rx Pricing Plan
The deals follow Trump’s pressure earlier this year, when he sent letters to 17 major drugmakers urging them to adopt “most preferred nation” pricing for Medicaid and to ensure new drugs are not launched in the U.S. at higher prices than abroad. Five companies, Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk and EMD Serono, had already reached similar agreements with the administration.
The big three companies, Regeneron, Johnson & Johnson and AbbVie, have yet to announce the deal. However, AbbVie is reportedly expected to reach a deal on Friday, according to Reuters.
Most Favored Nation Pricing is at the Center of Trump Drug Price Strategy
Meanwhile, as part of broader commitments, drugmakers agreed to apply most-preferred nation pricing to all new U.S. drug launches in commercial, public and cash-pay markets, including Medicare. Officials also said some of the revenue from foreign sales would be returned to the United States to offset costs, Reuters reported.
What’s Next After Trump’s Drug Price Announcement?
The companies have collectively pledged to invest more than $150 billion in the U.S. for research, development and manufacturing, but it is unclear whether that figure includes previous commitments. Merck said it would contribute $70 billion alone, according to a Reuters report. Some companies have also agreed to donate their pharmaceutical ingredients to the US strategic reserve.
Analysts noted that Medicaid already enjoys significant rebates, sometimes exceeding 80%, and Pfizer warned that expanded Medicaid rebates could squeeze prices and margins in 2026.
FAQ
Which companies are part of Trump’s drug price deal?
Companies include Merck, Bristol Myers Squibb, Gilead Sciences, Genentech, Novartis, Amgen, Sanofi, GSK and Boehringer Ingelheim.
How will TrumpRx impact Medicaid patients?
Most drugs sold through Medicaid will receive price reductions, which officials say could lead to big savings.
